Bolivia (Plurinational State of)Tuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.33 (0.21–0.48) 3.1 (2–4.5)
Mortality (HIV+TB only) 0.13 (0.11–0.16) 1.2 (1–1.5)
Prevalence  (includes HIV+TB) 20 (10–32) 187 (98–304)
Incidence  (includes HIV+TB) 13 (11–14) 120 (106–135)
Incidence (HIV+TB only) 0.51 (0.4–0.63) 4.8 (3.8–6)
         
Case detection, all forms (%) 64 (57–72)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 10 (7.7–13)
MDR-TB cases among notified pulmonary
TB cases
150 (71–230) 59 (45–77)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 476   428
Pulmonary, clinically diagnosed 449   32
Extrapulmonary 1 642   52
       
Total new and relapse 8 079    
Previously treated, excluding relapses 122    
Total cases notified 8 201    
Among 7 567 new cases:
394 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 238 (4%) 510 (80%) 748
Laboratory-confirmed RR-/MDR-TB cases     110
Patients started on MDR-TB treatment ***     55
TB/HIV 2014 Number (%)
TB patients with known HIV status 6 340 (77)
HIV-positive TB patients 262 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 125 (48)
HIV-positive TB patients on antiretroviral therapy (ART) 177 (68)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (85) 7 657
Previously treated cases registered in 2013 (77) 561
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (67) 43
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 5.3
Culture (per 5 million population) 29.4
Drug susceptibility testing (per 5 million population) 0.9
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 1.5
% Funded domestically 50%
% Funded internationally 50%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data